Skip to main content

Table 4 Indirect costs

From: Cost-effectiveness of human papillomavirus vaccination in Germany

Parameter Average absence from work (days)a Indirect costs (€, 2010 price level)b
Treatment of CIN 1 and CIN 2 15.9 15–19 years 336.50
20–24 years 835.26
25–29 years 965.33
30–34 years 977.31
35–39 years 1009.89
40–44 years 1063.18
45–49 years 1060.82
50–54 years 1010.30
55–59 years 853.97
60–64 years 410.89
Treatment of CIN 3 and CIS 21.3 15–19 years 450.79
20–24 years 1118.93
25–29 years 1293.18
30–34 years 1309.23
35–39 years 1352.87
40–44 years 1424.25
45–49 years 1421.10
50–54 years 1353.42
55–59 years 1144.00
60–64 years 550.44
Treatment of cervical cancer (all FIGO stages) 44.4 15–19 years 939.67
20–24 years 2332.42
25–29 years 2695.65
30–34 years 2729.11
35–39 years 2820.06
40–44 years 2968.87
45–49 years 2962.30
50–54 years 2821.22
55–59 years 2384.68
60–64 years 1147.39
Death due to cervical cancer (all FIGO stages) 63 (friction period) 15–19 years 1333.31
20–24 years 3309.52
25–29 years 3824.91
30–34 years 3872.38
35–39 years 4001.44
40–44 years 4212.58
45–49 years 4203.26
50–54 years 4003.08
55–59 years 3383.67
60–64 years 1628.06
Treatment of genital warts in females 7.7 15–64 years 30.81c
Treatment of genital warts in males 8.7 15–64 years 28.14c
  1. CIN cervical intraepithelial neoplasia, CIS carcinoma in situ, FIGO International Federation of Gynecology and Obstetrics
  2. aAverage duration of absence from work in patients who missed work because of illness
  3. bWeighted by age-specific employment rates of women
  4. cNot weighted by age-specific employment rates as the fraction of genital warts patients who missed work was estimated directly on the basis of a German study [42]